TOT BIOPHARM 2021 Interim Revenue Surges 78% to RMB23.13 million
HONG KONG, Aug 13, 2021 – (ACN Newswire via SEAPRWire.com) – TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Group”; stock code: 1875.HK), a biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies, announced today its unaudited interim results for the six months ended 30 June 2021. KEY MILESTONES IN 2021... » read more